Lineage-matched versus mismatched influenza B vaccine effectiveness following seasons of marginal influenza B circulation

Omer, Itay; Rosenberg, Alina; Sefty, Hanna; Pando, Rakefet; Mandelboim, Michal; Mendelson, Ella; Keinan‐Boker, Lital; Glatman‐Freedman, Aharona

doi:10.1016/j.vaccine.2021.12.056

Cited by 5 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the remaining 587 articles, 547 were discarded for not matching the inclusion criteria (of these, 62 were not further considered since no reported influenza cases were type B), 7 for being based on the WHO FluNet and/or GISAID database, 3 for being previous reports from the GIHSN, and 4 because of overlap with more recent and/or larger articles based on the same data sources. A total of 26 articles were included in the systematic review: their main characteristics are reported in Table 1 [ Soldevila 2022, Murillo-Zamora 2021, Korsun 2021, Panatto 2021, Pablo-Marcos 2020, Miron 2021, Hu 2021, Omer 2022, Olson 2022, Auvinen 2022, Kuzmanovska 2021, Wagatsuma 2022, Heinzinger 2021, Rios-Silva 2022, Suntronwong 2021, da Costa 2022, Melidou 2020, Huang 2022, O’Neill 2022, Kolosova 2022, Peck 2023, Chon 2023, Merced-Morales 2022, Melidou 2022, Sominina 2022, Song 2022 ]. Europe was the most represented area (12 articles, of which 2 reported findings from multiple countries in the WHO European Region), followed by Asia (n=6), North America (n=5), and Oceania and South America (n=1 each).…”

Section: Resultsmentioning

confidence: 99%

Is influenza B/Yamagata extinct and what public health implications could this have? An updated literature review and comprehensive assessment of global surveillance databases

Caini,

Meijer,

Nunes

et al. 2023

Preprint

View full text Add to dashboard Cite

Introduction: Early after the start of the COVID-19 pandemic, a major drop in the number of influenza B/Yamagata detections was observed globally. Given the potential public health implications, particularly with regards to influenza vaccination, we conducted a systematic review of influenza B/Yamagata virus circulation data from multiple complementary sources of information. Methods: We searched articles published until 20th March 2023 in PubMed and EMBASE; examined epidemiological and virological influenza data for 2020-2023 contained in the publicly available WHO-FluNet and GISAID (Global Initiative on Sharing All Influenza Data) global databases, or collected by the multi-national Global Influenza Hospital Surveillance Network (GIHSN) study; and looked for influenza data in the webpages of respiratory viruses surveillance systems from countries worldwide. Results: Highly consistent findings were found across all sources of information, with a progressive decline of influenza B/Yamagata detections from 2020 onwards across all world regions, both in absolute terms (total number of cases), the positivity rate, and as a fraction of influenza B detections. Isolated influenza B/Yamagata cases continue to be sporadically reported, and these are typically vaccine-derived, mistaken data entries or under investigation. Discussion: While it is still too early to conclude that B/Yamagata is (or will soon become) extinct, the current epidemiological and virological data call for a rapid response in terms of influenza prevention practices, particularly regarding the formulation of influenza vaccines. The current epidemiological situation is unprecedented in recent decades, underlying the importance of continuously and carefully monitoring the circulation of influenza viruses (as well as SARS-CoV-2 and the other respiratory viruses) in the coming years.

show abstract

Section: Resultsmentioning

confidence: 99%

Is influenza B/Yamagata extinct and what public health implications could this have? An updated literature review and comprehensive assessment of global surveillance databases

Caini,

Meijer,

Nunes

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Nevertheless, the influenza A(H3N2) infection rate was lower in Israel compared with the United States and Europe, which may have been due to immunity gained in the 2021–2022 winter season when influenza A(H3N2) circulated. In contrast, influenza A(H1N1)pdm09 last circulated in Israel in the winter season of 2019–2020, which may explain its dominance in Israel in 2022–2023 ( Fratty et al, 2022 ; Omer et al, 2022 ; Malosh et al, 2023 ). Overall, the prevalence of influenza A strains tends to shift each year between influenza A(H1N1)pdm09 and influenza A(H3N2), as seen prior to the emergence of SARS-CoV-2 in Israel [ Europe Centers for Disease Control and Prevention (ECDC), 2023 ].…”

Section: Discussionmentioning

confidence: 99%

Influenza vaccine compatibility among hospitalized patients during and after the COVID-19 pandemic

Fratty,

Jurkowicz,

Zuckerman

et al. 2024

Front. Microbiol.

Self Cite

View full text Add to dashboard Cite

IntroductionFollowing the significant decrease in SARS-CoV-2 cases worldwide, Israel, as well as other countries, have again been faced with a rise in seasonal influenza. This study compared circulating influenza A and B in hospitalized patients in Israel with the influenza strains in the vaccine following the 2021–2022 winter season which was dominated by the omicron variant.MethodsNasopharyngeal samples of 16,325 patients were examined for the detection of influenza A(H1N1)pdm09, influenza A(H1N1)pdm09 and influenza B. Phylogenetic trees of hemagglutinin were then prepared using sanger sequencing. Vaccine immunogenicity was also performed using the hemagglutination inhibition test.ResultsOf the 16,325 nasopharyngeal samples collected from hospitalized patients between September 2021 (Week 40) and April 2023 (Week 15), 7.5% were found to be positive for influenza. Phylogenetic analyses show that in the 2021–2022 winter season, the leading virus subtype was influenza A(H3N2), belonging to clade 3C.2a1b.2a.2. However, the following winter season was dominated by influenza A(H1N1)pdm09, which belongs to clade 6B.aA.5a.2. The circulating influenza A(H1N1)pdm09 strain showed a shift from the vaccine strain, while the co-circulating influenza A(H3N2) and influenza B strains were similar to those of the vaccine. Antigenic analysis coincided with the sequence analysis.DiscussionInfluenza prevalence during 2022–2023 returned to typical levels as seen prior to the emergence of SARS-CoV-2, which may suggest a gradual viral adaptation to SARS-CoV-2 variants. Domination of influenza A(H1N1)pdm09 was observed uniquely in Israel compared to Europe and USA and phylogenetic and antigenic analysis showed lower recognition of the vaccine with the circulating influenza A(H1N1)pdm09 in Israel compared to the vaccine.

show abstract

Immunogenicity and safety of an egg culture-based quadrivalent inactivated non-adjuvanted subunit influenza vaccine in subjects ≥3 years: A randomized, multicenter, double-blind, active-controlled phase III, non-inferiority trial

Zhang¹,

Wang

Jia³

et al. 2022

Vaccine

View full text Add to dashboard Cite

Lineage-matched versus mismatched influenza B vaccine effectiveness following seasons of marginal influenza B circulation

Cited by 5 publications

References 19 publications

Is influenza B/Yamagata extinct and what public health implications could this have? An updated literature review and comprehensive assessment of global surveillance databases

Is influenza B/Yamagata extinct and what public health implications could this have? An updated literature review and comprehensive assessment of global surveillance databases

Influenza vaccine compatibility among hospitalized patients during and after the COVID-19 pandemic

Immunogenicity and safety of an egg culture-based quadrivalent inactivated non-adjuvanted subunit influenza vaccine in subjects ≥3 years: A randomized, multicenter, double-blind, active-controlled phase III, non-inferiority trial

Contact Info

Product

Resources

About